Cardiotoxicity following #CART therapy is an emerging area of concern for both hematologists & cardiologists.

We heard from Dr Arjun Ghosh (London Cardio-Oncology) of UCLH, who shared insights into how this complication can be addressed:
🎥 ow.ly/UeWE50RzCTe

#ImmunoOnc #BSH2024 #HemOnc BSH - Haematology

Check out this week's podcast, featuring experts C. Ola Landgren, M.D., Suzanne Lentzsch, MD, PhD, Suzanne Trudel & Tom Martin from #iwMyeloma24 , who discuss approaching bone disease, updates with isatuximab & belamaf & more!

🎧 ow.ly/kxe950RBcRr

#MMsm #HemOnc #ImmunoOnc

#hncsm #ImmunoOnc #radonc

Managing immune checkpoint-blocking antibody side effects - Michael Postow #ASCO15 Education Book ow.ly/ysd9304fCS7 #ImmunoOnc #irAE

Pembrolizumab in Patients w/ Metastatic Breast Cancer w/ High Tumor Mutational Burden: Results From the Targeted Agent & Profiling Utilization Registry (TAPUR) Study [Apr 12, 2021] AjjaiAlva et al. @JCO_ASCO ow.ly/Iohy50Eum4z #bcsm #ImmunoOnc #PrecisionMedicine ASCO

Twitter During ASCO 2011-16: Advanced Metrics & User Trends [May 17, 2017] Naveen Pemmaraju, MD Mike Thompson, MD, PhD, FASCO Ruben A. Mesa, MD Tejas Desai, MD MBA JCO Oncology Practice ow.ly/XFfs30bT6ia #ASCO24 #ImmunoOnc

Assessment of Tumor Mutational Burden [ #TMB ] and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy [May 2, 2023] Charu Aggarwal, MD, MPH, FASCO et al. Jyoti D Patel JAMA Network Open bit.ly/3NsoeCj #ImmunoOnc #PrecisionMedicine #lcsm Tempus

Society for Immunotherapy of Cancer (SITC, Society for Immunotherapy of Cancer) clinical practice guideline on immune checkpoint inhibitor-related adverse events [Jun 25, 2021] Dr. Julie Brahmer et al. #JITC Journal for ImmunoTherapy of Cancer ow.ly/o0x950Fo3Id #ImmunoOnc #irAE

🎥Dr Adam Januszewski of St Bartholomew's Hospital shares insights from a session at #BTOG24 on novel therapeutics for #lungcancer , including ADCs and BiTEs, highlighting promising trials and challenges ahead:

➡️ow.ly/XRQa50RwqSn⬅️

BTOG #LCSM #ImmunoOnc

Association of Baseline Tumor-Specific Neoantigens and CD8+ T-Cell Infiltration With Immune-Related Adverse Events Secondary to Immune Checkpoint Inhibitors [Feb 8, 2024] Csaba Kerepesi et al. JCO Precision Oncology
ascopubs.org/doi/full/10.12… #PrecisionMedicine #ImmunoOnc #irAE

Society for Immunotherapy of Cancer (Society for Immunotherapy of Cancer) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology [Mar 31, 2023] Jarushka Naidoo et al. Journal for ImmunoTherapy of Cancer
jitc.bmj.com/content/11/3/e…… #ImmunoOnc #irAE

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer [Jul 12, 2022] Chen et al. The Oncologist
academic.oup.com/oncolo/advance… #ImmunoOnc #irAE HT garyg

Molecular alterations with hyperprogression in lung cancer patients treated with immune checkpoint inhibitors in a large health system - Tadesse et al. J Clin Oncol 38: 2020 (suppl; abstr e15082) #ASCO20 ow.ly/pSnJ30qGanS #ImmunoOnc #lcsm

Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis [Sep 5, 2019] Abu-Sbeih et al. Journal for ImmunoTherapy of Cancer ow.ly/OrzK30q1774 #ImmunoOnc #IDonc

Immune Checkpoint Inhibitor Toxicity in 2018 [Oct 4, 2018] Johnson et al. JAMA ow.ly/UYai30m6DBY #ImmunoOnc #irAE

Management of Immune-Related Adverse Events (irAEs) in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Clinical Practice Guideline [Feb 14, 2018] Brahmer et al. Journal of Clinical Oncology ow.ly/kadR30iq5Ke #ImmunoOnc #SuppOnc #irAE

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (Society for Immunotherapy of Cancer) Toxicity Management Working Group [Nov 21, 2017] Puzanov et al. Journal for ImmunoTherapy of Cancer ow.ly/Sv7330qixNk #ImmunoOnc #irAE HT Tatiana Prowell, MD

#EBMT24 | Florent Malard (@Sorbonne_Univ_) shares the findings of a survey comparing the use of axi-cel and tisa-cel for aggressive B-cell #Lymphoma across 67 European centers:

👉 ow.ly/pkoT50Rvxrz

#CART #ImmunoOnc #HemOnc #LYMsm #DLBCL #NonHodgkinLymphoma The EBMT

Comparative analysis of the tumor immune microenvironment (TIME) in primary & metastatic sites of microsatellite stable (MSS) & microsatellite instability-high (MSI) colorectal cancer [10/22/23] Dr. Marwan G. Fakih et al Jun Gong #ESMO23 Abst 574P cslide.ctimeetingtech.com/esmo2023/atten… #crcsm #ImmunoOnc